如果我是那種只看單面資訊就不會把NIH連結貼上來，本來兩方面資料都有參考價值。
不過，我從來只建議自己思考，我只點出問題，剩下個人就靠自己去挖了。

倒是你老是一下說人就糾結，一下告訴別人少看社群媒體資料，
然後看一篇我貼出來的東西餵了古狗翻譯，就以為自己看得多，別人看得少，你不覺得好笑？

加油啊！

你的推論也很單面化啊... 這麼直接就認為別人只看了你貼的文章而已...
你真的要多加油啊... 多思考啊...

英國衛報/Theguardian Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns
Melissa Davey/Thu 15 Jul 2021 18.30 BST

The preprint endorsing ivermectin as a coronavirus therapy has been widely cited, but independent researchers find glaring discrepancies in the data.

支持伊維菌素作為冠狀病毒療法的預印本已被廣泛引用，但獨立研究人員發現數據存在明顯差異.
---
倫敦的醫學生傑克·勞倫斯（Jack Lawrence）是最早發現該論文存在嚴重問題的人之一，這導致了論文被撤回。他第一次知道 Elgazzar 預印本是他的一位講師分配給他的，這是他碩士學位的一部分。他發現論文的介紹部分似乎幾乎完全抄襲了。

似乎作者已經通過同義詞庫運行了新聞稿和網站上關於伊維菌素和 Covid-19 的整個段落來更改關鍵詞。勞倫斯說：“幽默地說，這導致他們有一次將‘嚴重急性呼吸系統綜合症’變成了‘極度嚴重的呼吸系統綜合症’。”

數據在勞倫斯看來也很可疑，原始數據顯然多次與研究方案相矛盾。

“作者聲稱只對 18-80 歲的人進行了這項研究，但數據集中至少有 3 名患者未滿 18 歲，”勞倫斯說。

“作者聲稱他們在 2020/6/8至 9/20之間進行了這項研究，但根據原始數據，大多數死亡患者都入院並在 6/8之前死亡。數據的格式也很糟糕，其中包括一名在 06/31/2020 不存在的日期出院的患者。”

---

布朗創建了一份全面的文件，揭示了許多數據錯誤、差異和問題，並將其提供給了衛報。根據他的發現，作者在患者之間清楚地重複了數據。

“主要錯誤在於，至少有 79 份患者記錄明顯是其他記錄的複製品，”布朗告訴衛報。“這當然是最難解釋為無辜的錯誤，特別是因為克隆甚至不是純複製品。有跡象表明，他們試圖改變一兩個領域，讓它們看起來更自然。”

---
布朗創建了一份全面的文件，揭示了許多數據錯誤、差異和問題，並將其提供給了衛報。
Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19 15 July 2021

Slovakia Becomes the First EU Nation to Formally Approve Ivermectin for Both Prophylaxis and Treatment for COVID-19 Patients
斯洛伐克成為第一個正式批准伊維菌素用於武漢肺炎患者預防和治療的歐盟國家

The Slovakia Republic’s Minister of Health has formerly registered Ivermectin as an approved prophylaxis and treatment for SARS-CoV-2, the virus behind COVID-19. In breaking news, the authorization occurred yesterday as doctors received the news that they could proceed with formally authorized prescriptions both in hospitals and outpatient. On January 26, Health Minister Marek Krajci granted a permit for the unregistered drug as the drug has already been in use on a compassionate basis over the past half year. TrialSite interviewed Ondrej Halgas, a researcher from University of Toronto and originally from Slovakia. Halgas has been actively involved with a network organizing and lobbying for the drug’s approval during the pandemic. This landlocked Eastern European nation of 5.4 million people, a member of the European Union since 2004, just made history.

A biochemist with the University of Toronto, Mr. Halgas, was just also showcased in a recent press release on this subject. TrialSite was able to get in touch with him to learn more.

The actual authorization was the result of networks of health care professionals, journalists and other health care activists who have been working diligently to raise awareness as to the mounting efficacy data in the context of the COVID-19 pandemic.

In fact, Ondrej Halgas and the TrialSite Network dovetails nicely with the COVID-19 Front Line Critical Care Alliance (FLCCC) and other academics, journalists and physicians working to raise awareness about this important therapeutic option during the pandemic.

Slovakia the First EU Nation to Authorize Ivermectin

The antiparasitic drug was authorized by the Health Minister after a formal request from professor Ivan Schréter, CSc, the Chief Expert for Infectious Disease with the Ministry of Health of the Slovak Republic. A conditional authorization, TrialSite interprets that the registration is valid for a six (6) month period for hospitals and ambulatory care for the indication of prophylaxis and treatment of patients with COVID-19. The medicine will also be available at licensed prescription pharmacies.

The Path to Approval

A scientist from University of Toronto, Ondrej Halgas, expressed pride that his home country was able to become the very first nation in Europe to formally approve this drug as a complement to vaccines and other treatments. In an interview with TrialSite’s Daniel O’Connor, Halgas shared he has been collaborating with physicians such as Dr. Pierre Kory and Paul E. Marik as well as others. In Germany, apparently Ivermectin use has grown, reports Halgas. He was in touch with a physician group there that treated the elderly at a nursing home.

The mortality rate in nursing homes in that European country (Germany) is about 25% to 30%. After treating about 100 residents with Ivermectin, that rate in one case series apparently went down to about 5%—a huge difference. Of course, this isn’t the result of a formal study but nonetheless represents more real world data points.

Supply Challenges

Ondrej Halgas reports that supply is another matter. Unlike in many other EU countries, such as Austria, in Slovakia, Ivermectin was available only for animals and as a cream for humans. To date, at least one hospital in the nation’s second largest city has been influential in the importance of the drug under some waiver. They have seen markedly improved results, according to Halgas.

This latest edict by the Health Minister now allows for the importation. Doctors and hospitals have been importing the drug from Austria and even as far away as India, and it’s not clear how the country’s predominantly national health system will work to efficiently and effectively import the drug. Presently, the country has three payers, including one national payer and two private sector groups.

The importation is an area that TrialSite will continue to monitor.

Call to Action: TrialSite predicts that more nations will authorize this drug for use as prophylaxis and treatment targeting COVID-19 at least for the duration of the pandemic. Sign up for the daily newsletter for updates.

參考這個：

印度、墨西哥沒有小針針病例大幅下降原因是……主流媒體不報導！
https://www.youtube.com/watch?v=ytfUF61Rbk4

能不能有一些影片佐證當地真的有普遍在吃伊維菌素的藥?
是哪一款呢?

我查一下墨西哥的確診數最近還在上升耶
死亡數也沒有低到哪裡去

半年了, 應該有實際成果可以發表了?
---
Slovakia Becomes the First EU Nation to Formally Approve Ivermectin for Both Prophylaxis and Treatment for COVID-19 Patients
TrialSite Staff January 28, 2021

.....................